These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16971803)

  • 1. Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.
    Hinz T; Buchholz CJ; van der Stappen T; Cichutek K; Kalinke U
    J Immunother; 2006; 29(5):472-6. PubMed ID: 16971803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J; Egan W; Vicari G; Furesz J; Schild G
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
    Nicolette CA; Healey D; Tcherepanova I; Whelton P; Monesmith T; Coombs L; Finke LH; Whiteside T; Miesowicz F
    Vaccine; 2007 Sep; 25 Suppl 2():B47-60. PubMed ID: 17669561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
    Klammer M; Roddie PH
    Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
    Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS; Cichutek K
    Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell fusion: from hybridoma to dendritic cell-based vaccine.
    Gong J; Koido S; Calderwood SK
    Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell vaccines in acute leukaemia.
    Duncan C; Roddie H
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):521-41. PubMed ID: 18790453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technical challenges facing therapeutic cancer vaccines.
    Ward S; Copier J; Dalgleish A
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):168-77. PubMed ID: 18283604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-tumor effects induced by fusion of interleukin-18 gene transfected NCI-H460 lung cancer cell line with dendritic cells].
    Zhang ZY; Wu JM
    Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):17-20. PubMed ID: 17575687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-modified cellular vaccines: technologic aspects and clinical problems.
    Mackiewicz J; Mackiewicz A
    Transplant Proc; 2010 Oct; 42(8):3287-92. PubMed ID: 20970673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.